Thu, Jul 24, 2014, 12:06 AM EDT - U.S. Markets open in 9 hrs 24 mins

Recent

% | $
Click the to save as a favorite.

Alnylam Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • robert.vince robert.vince Oct 9, 2012 11:38 AM Flag

    Alnylam Announces Tuschl II Key Patent Claims Upheld in Invalidation Trial in Japan

    Based on this statement, it looks like this was a positive announcement:

    “We are extremely pleased with the outcome of the invalidation trial which resulted in key claims from the Tuschl II ’895 patent being upheld in Japan. This affirms our belief in the validity of these claims and the groundbreaking nature of the Tuschl II invention forming the basis of this critical patent family,” said Laurence Reid, Ph.D., Senior Vice President, Chief Business Officer at Alnylam. “Tuschl II remains a valuable patent in our overall broad estate of patents important for the development and commercialization of RNAi therapeutics, and a patent family to which we are the exclusive licensee. We look forward to the continued advancement of the Tuschl II patent family worldwide in conjunction with many other Alnylam-held patents and pending patent applications.”

 
ALNY
55.86+0.60(+1.09%)Jul 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.